Skip to content

News

OCRFA Funded Study Explores New Role of Estrogen in Anti-Tu...

OCRFA Funded Study Explores New Role of Estrogen in Anti-Tumor Immunity

(October 31, 2016) Estrogen signaling is a known factor in how certain estrogen receptive (ER positive) tumors grow in breast and ovarian cancers. That signaling, which can promote malignant tumor growth, can sometimes be effectively treated with anti-estrogen therapy, such as tamoxifen. What is less understood, and currently being studied at the Wistar Institute, is … Continued

OCRFA applauds FDA’s statement on ovarian cancer screening ...

OCRFA applauds FDA’s statement on ovarian cancer screening test

On September 7th, the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated. The FDA states, “despite extensive research and published studies, there are currently no screening tests for ovarian cancer that are sensitive enough to reliably screen for ovarian cancer without a … Continued

Risk-reducing Oophorectomy is Risky, Study Shows

Risk-reducing Oophorectomy is Risky, Study Shows

A Mayo Clinic research team has found evidence suggesting that premenopausal women who are not at high risk of ovarian cancer should not have their ovaries removed for the purpose of cancer prevention. Premature removal of the ovaries can lead to a higher risk of anywhere from 8 to 18 chronic health conditions including coronary … Continued

Niraparib Significantly Improves Outcome of Ovarian Cancer ...

Niraparib Significantly Improves Outcome of Ovarian Cancer Patients

(October 11, 2016) According to research published this month in the New England Journal of Medicine, the PARP inhibitor niraparib improves progression free survival in recurrent, platinum-sensitive women both with and without germline BRCA mutations. In a randomized, double-blind, phase III trial of over 550 women both with and without germline BRCA mutations, researchers found … Continued

Meet Researcher Hui Shen, PhD

Meet Researcher Hui Shen, PhD

Meet a Researcher: We had the chance to interview Hui Shen, PhD, a 2016 Liz Tilberis Early Career Award grantee to get to know her! Read our interview here. OCRFA: Tell us about yourself. Dr. Hui Shen: My name is Hui Shen. I am originally from China, and had lived in Hong Kong and Los … Continued

Stand Up to Cancer Update Webinar

Stand Up to Cancer Update Webinar

OCRFA and Dr. Elizabeth Swisher spoke about the exciting progress being made by the Stand Up to Cancer Ovarian Cancer Dream Team! The SU2C Ovarian Cancer Dream Team, funded by OCRFA and NOCC, got to work on year ago. Dr. Swisher, a gynecologic oncologist at the University of Washington and co-leader of the Dream Team, … Continued

Low Volume Surgeons Lead to Poorer Outcomes

Low Volume Surgeons Lead to Poorer Outcomes

(October 5, 2016) A new analysis published in the American Journal of Obstetrics and Gynecology determined the impact of gynecologic surgeon volumes on patient outcomes. Reviewing fourteen studies that involved over 700,000 women, the researchers found that low-volume surgeons (categorized as those performing the procedure approximately once a month or less) were found to have … Continued

OCRFA Research Shows Drugs Help Anti-Tumor Immunity

OCRFA Research Shows Drugs Help Anti-Tumor Immunity

(October 5, 2016) A team of researchers, including senior author and former OCRFA grantee Rugang Zhang, PhD, have been studying the relationship between PD-1 and PD-L1, a protein and an accompanying molecule, and t-cells, which are a body’s natural defense against tumor growth. PD-L1 can be found on both cancer cells and healthy cells but, … Continued

Report from the Biennial Ovarian Cancer Research Symposium

Report from the Biennial Ovarian Cancer Research Symposium

Research Advocate, Annie Ellis, recently attended the Biennial Ovarian Cancer Research Symposium presented by the Rivkin Center for Ovarian Cancer and the American Association for Cancer Research. Read her report, check out a poster on Beyond RECIST 1.1 and a poster on MAGENTA-Making Genetic Testing More Accessible.

Update on ROCA Test

Update on ROCA Test

On September 13th, Abcodia Incorporated, the makers of the ROCA Test, released this statement*, following the safety guidance put out by the FDA last week. ROCA Test sales are now suspended in the United States. *Note: The original publication of this article linked to an article that has since been archived. For more updated information, please visit … Continued

#30DaysofTeal: Day 5

#30DaysofTeal: Day 5

Meet Researcher Kris Wood, PhD! Q&A with Kris Wood, PhD Duke University 2015 Liz Tilberis Award OCRFA: Tell me about yourself. Kris Wood: I grew up in Georgetown, KY, a rural town in the central part of the state. My family lived in a house on my grandfather’s farm, which was a wonderful place to … Continued

SGO and ASCO Agree on Guidelines for Common Type of Ovarian...

SGO and ASCO Agree on Guidelines for Common Type of Ovarian Cancer

(August 16, 2016) While primary cytoreductive surgery followed by chemotherapy is the standard of care for newly diagnosed women with advanced ovarian cancer, newly issued practice guidelines suggest that some patients may benefit more from first-line neoadjuvant chemotherapy (NACT) and followed by surgery. Last week, the Society for Gynecologic Oncology (SGO) and the American Society … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.